Development

Dengli Medical Technology (Nanjing) Co., Ltd., founded in July 2025, specialises in the commercial application of low‑temperature plasma technology for pet dermatology. Led by Dr. Wu Guangmei (PhD from TU Berlin and former J&J executive), the core team brings together experts from the Chinese Academy of Sciences Suzhou Institute, Jiangsu Academy of Agricultural Sciences, and Nanjing Agricultural University. Its proprietary high‑voltage nanosecond pulse plasma generates plasma directly from air without external gas, achieving 99.9% sterilisation in 30 seconds, with a treatment area much larger than rivals, and offers pain‑free, non‑invasive, no‑drug‑resistance therapy that cuts treatment cycles by 50%.

Product lines cover three series: “Dengchong” (pet skin care), “Dengjing” (space disinfection), and “Dengli” (human‑pet co‑healing). Pilot orders have been secured from clients in Jiangsu and Guangdong, and 200 clinical trials on dogs and cats are underway with research institutes. Short‑term goals focus on capturing 30% of Nanjing’s pet hospital market; mid‑term plans include expanding into smart home disinfection with annual revenue of ¥30 million; long‑term, the company aims to enter Europe using the founder’s German connections, building a global human‑pet health ecosystem.